The Food and Drug Administration (FDA) has approved Tevimbra® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the ...

Medically reviewed by Qin Rao, MD Barrett's esophagus occurs when the lining of the esophagus, the tube that runs from the ...

A Midtown-based diagnostics company raised capital in a deal to advance its novel approach to screening for the risk factors ...

Background: Neoadjuvant therapy is widely used for esophageal cancer (EC), but optimal treatment regimens and predictive factors for outcomes remain unclear. This study retrospectively analyzed data ...

Breast cancer patients who underwent postmastectomy breast reconstruction had lower sexual well-being scores compared with ...

Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), is one of the most prevalent digestive malignancies, with a 5-year survival rate of only 20%. Although some cancer ...

Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...

The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...

Patients with PD-L1-positive tumors lived more than seven months longer on Tevimbra added to chemotherapy compared to just chemo.

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...

Weeks after the Labor Department added coverage for cancers affecting women firefighters, all information is deleted from the ...

The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...